JBCHEPHARM Stock Overview
Manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 4/6 |
Past Performance | 6/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
J. B. Chemicals & Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹1,891.35 |
52 Week High | ₹2,030.00 |
52 Week Low | ₹1,244.45 |
Beta | -0.044 |
11 Month Change | 1.85% |
3 Month Change | 5.63% |
1 Year Change | 40.56% |
33 Year Change | 122.90% |
5 Year Change | 1,021.13% |
Change since IPO | 2,404.27% |
Recent News & Updates
Recent updates
J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) Business Is Yet to Catch Up With Its Share Price
Sep 24Most Shareholders Will Probably Agree With J. B. Chemicals & Pharmaceuticals Limited's (NSE:JBCHEPHARM) CEO Compensation
Aug 15J. B. Chemicals & Pharmaceuticals Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 11These 4 Measures Indicate That J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Using Debt Reasonably Well
Jun 28J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Apr 19J. B. Chemicals & Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models
Feb 09J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM) Not Flying Under The Radar
Dec 22We Think J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Can Stay On Top Of Its Debt
Nov 29J. B. Chemicals & Pharmaceuticals' (NSE:JBCHEPHARM) Dividend Will Be Increased To ₹9.25
Aug 03J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Due To Pay A Dividend Of ₹8.50
Feb 11Is J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Using Too Much Debt?
Dec 03A Look At The Intrinsic Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Sep 21J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Seems To Use Debt Quite Sensibly
Aug 03Estimating The Fair Value Of J. B. Chemicals & Pharmaceuticals Limited (NSE:JBCHEPHARM)
Jun 15Does J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Have A Healthy Balance Sheet?
Mar 29J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Has Re-Affirmed Its Dividend Of ₹8.50
Feb 16With EPS Growth And More, J. B. Chemicals & Pharmaceuticals (NSE:JBCHEPHARM) Is Interesting
Jan 27Shareholder Returns
JBCHEPHARM | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 4.7% | -0.8% | -0.9% |
1Y | 40.6% | 60.3% | 39.7% |
Return vs Industry: JBCHEPHARM underperformed the Indian Pharmaceuticals industry which returned 58.4% over the past year.
Return vs Market: JBCHEPHARM exceeded the Indian Market which returned 38.5% over the past year.
Price Volatility
JBCHEPHARM volatility | |
---|---|
JBCHEPHARM Average Weekly Movement | 3.5% |
Pharmaceuticals Industry Average Movement | 6.1% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.4% |
10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: JBCHEPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: JBCHEPHARM's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 5,311 | Nikhil Chopra | www.jbpharma.com |
J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company’s API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms.
J. B. Chemicals & Pharmaceuticals Limited Fundamentals Summary
JBCHEPHARM fundamental statistics | |
---|---|
Market cap | ₹294.59b |
Earnings (TTM) | ₹5.87b |
Revenue (TTM) | ₹35.92b |
50.2x
P/E Ratio8.2x
P/S RatioIs JBCHEPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
JBCHEPHARM income statement (TTM) | |
---|---|
Revenue | ₹35.92b |
Cost of Revenue | ₹12.44b |
Gross Profit | ₹23.48b |
Other Expenses | ₹17.61b |
Earnings | ₹5.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 37.80 |
Gross Margin | 65.37% |
Net Profit Margin | 16.34% |
Debt/Equity Ratio | 12.9% |
How did JBCHEPHARM perform over the long term?
See historical performance and comparison